Drotrecogin alfa

Generic Name
Drotrecogin alfa
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
98530-76-8
Unique Ingredient Identifier
JGH8MYC891
Background

Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a major study indicated that it was not effective in improving out...

Indication

For reduction of mortality in patients with severe sepsis.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Regression Discontinuity Design to Evaluate of Drotrecogin Alpha Effectiveness

Completed
Conditions
Sepsis
First Posted Date
2016-07-26
Last Posted Date
2016-07-26
Lead Sponsor
Boston Medical Center
Target Recruit Count
12492
Registration Number
NCT02843685
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Boston Medical Center, Boston, Massachusetts, United States

Administration of Human Protein C Concentrates in Patients With Sepsis and Septic Shock.

First Posted Date
2011-08-08
Last Posted Date
2015-12-02
Lead Sponsor
University of Roma La Sapienza
Target Recruit Count
60
Registration Number
NCT01411670
Locations
๐Ÿ‡ฎ๐Ÿ‡น

Departement of Anesthesiology and Intensive Care of the University of Rome La Sapienza, Rome, Italy

Activated Protein C in Severe Acute Pancreatitis

Phase 4
Completed
Conditions
Acute Pancreatitis
Interventions
Drug: Activated protein C
First Posted Date
2009-11-20
Last Posted Date
2010-10-14
Lead Sponsor
Helsinki University Central Hospital
Target Recruit Count
32
Registration Number
NCT01017107
Locations
๐Ÿ‡ซ๐Ÿ‡ฎ

Helsinki University Central Hospital, Helsinki, Finland

Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock

Phase 3
Completed
Conditions
Sepsis
Interventions
Drug: Placebo
Drug: Drotrecogin alfa (activated)
First Posted Date
2008-01-30
Last Posted Date
2012-09-18
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
1696
Registration Number
NCT00604214
Locations
๐Ÿ‡ฌ๐Ÿ‡ง

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom

An Open Label Study of Severe Sepsis in Adults

Phase 4
Completed
Conditions
Severe Sepsis
Interventions
Drug: drotrecogin alfa (activated)
First Posted Date
2007-12-06
Last Posted Date
2007-12-06
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
130
Registration Number
NCT00568893
Locations
๐Ÿ‡ง๐Ÿ‡ช

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wilrijk, Belgium

The Study of Drotrecogin Alfa (Activated) in Adult Patients With Severe Sepsis at a Low Risk of Death

Phase 3
Completed
Conditions
Sepsis
Interventions
Drug: Placebo
Drug: Drotrecogin alfa (activated)
First Posted Date
2007-12-06
Last Posted Date
2007-12-06
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
2640
Registration Number
NCT00568737
Locations
๐Ÿ‡ซ๐Ÿ‡ท

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gleize, France

Activated Protein C in Acute Stroke Trial

Phase 2
Terminated
Conditions
Stroke
Interventions
Drug: Activated Protein C
First Posted Date
2007-09-21
Last Posted Date
2016-10-24
Lead Sponsor
University of Rochester
Target Recruit Count
12
Registration Number
NCT00533546
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Loyola University Medical Center, Maywood, Illinois, United States

๐Ÿ‡บ๐Ÿ‡ธ

Maimonides Medical Center, Brooklyn, New York, United States

๐Ÿ‡บ๐Ÿ‡ธ

Rochester General Hospital, Rochester, New York, United States

and more 6 locations

Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated)

Phase 2
Completed
Conditions
Severe Sepsis
Interventions
Drug: Drotrecogin alfa (activated)
First Posted Date
2006-10-11
Last Posted Date
2010-12-16
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
486
Registration Number
NCT00386425
Locations
๐Ÿ‡ฌ๐Ÿ‡ง

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, West Midlands, United Kingdom

Hemodynamic and Perfusion Response to Drotrecogin Alfa (Activated) in Patients With Septic Shock

Phase 4
Completed
Conditions
Sepsis
Septic Shock
First Posted Date
2006-01-19
Last Posted Date
2009-09-02
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
43
Registration Number
NCT00279214
Locations
๐Ÿ‡บ๐Ÿ‡ธ

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Akron, Ohio, United States

Extended Therapy of Drotrecogin Alfa (Activated) 4 vs 7 Days Infusion

Phase 3
Completed
Conditions
Sepsis
Hypotension
First Posted Date
2005-09-19
Last Posted Date
2007-10-12
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
200
Registration Number
NCT00190788
Locations
๐Ÿ‡ซ๐Ÿ‡ท

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France

ยฉ Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy